Trusted Resources: News & Meetings

Latest announcements and gatherings

Burosumab Safe, Effective in Children With Rare Form of Rickets

Young children with X-linked hypophosphatemia saw significant improvements in rickets and phosphate homeostasis after 63 weeks of biweekly treatment with the monoclonal antibody burosumab, according to findings published in The Lancet Diabetes & Endocrinology.

X-linked hypophosphatemia causes low levels of phosphorus in the blood due to excess fibroblast growth factor 23 production, leading to impaired bone growth and development in children and adolescents and problems with bone mineralization throughout a person’s life. The FDA approved burosumab (Crysvita, Ultragenyx) for the treatment of X-linked hypophosphatemia in April.


Burosumab Safe, Effective In Children With Rare Form Of Rickets

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.